108 related articles for article (PubMed ID: 36319183)
1. [Efficacy and safety of daratumumab in patients with relapsed/refractory multiple myeloma].
Zhao AL; Tang WJ; Li Y; Liao Y; Li H; Wang J; Shen K; Yang YF; Xu J; Zhang L; Zheng YH; Niu T
Zhonghua Yi Xue Za Zhi; 2022 Nov; 102(41):3304-3311. PubMed ID: 36319183
[No Abstract] [Full Text] [Related]
2. [Analysis of efficacy and safety of daratumumab-containing regimen in relapsed and refractory multiple myeloma patients].
Yu QR; Zhou X; Wu HY; Hao LM; Li XM; Zhong YP
Zhonghua Yi Xue Za Zhi; 2024 Feb; 104(7):521-525. PubMed ID: 38317364
[No Abstract] [Full Text] [Related]
3. Efficacy and safety of melflufen plus daratumumab and dexamethasone in relapsed/refractory multiple myeloma: results from the randomized, open-label, phase III LIGHTHOUSE study.
Pour L; Szarejko M; Bila J; Schjesvold FH; Spicka I; Maisnar V; Jurczyszyn A; Grudeva-Popova Z; Hájek R; Usenko G; Thuresson M; Norin S; Jarefors S; Bakker NA; Richardson PG; Mateos MV
Haematologica; 2024 Mar; 109(3):895-905. PubMed ID: 37646660
[TBL] [Abstract][Full Text] [Related]
4. Daratumumab in Indian patients with relapsed and refractory multiple myeloma: a prospective, multicenter, phase IV study.
Kumar L; Melinkeri S; Ganesan P; Kumar J; Biswas G; Kilara N; Pathalingappa H; Prasad S; Jain M; Mishra SK; Prasad S; Boyella PK; Sahoo RK; Bondarde S; Shah S; Rege M; Deb U; Korde T; Dixit J
Future Oncol; 2024 Feb; 20(4):191-205. PubMed ID: 38116642
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of daratumumab, pomalidomide, and dexamethasone versus daratumumab, carfilzomib, and dexamethasone in daratumumab-naïve relapsed multiple myeloma.
Dima D; Mansour R; Davis JA; Minchak M; Goel U; Atallah R; Logan E; Tabak C; Rashid A; Ahmed N; Abdallah AO; Hashmi H
Eur J Haematol; 2024 Jun; 112(6):975-983. PubMed ID: 38382632
[TBL] [Abstract][Full Text] [Related]
6. Clinical outcomes of pomalidomide-based and daratumumab-based therapies in patients with relapsed/refractory multiple myeloma: A real-world cohort study in China.
Han X; Jiang X; He J; Zheng G; Xiong Y; Wen Y; Yang Y; He D; Chen Q; Zhao Y; Li Y; Wu W; Cai Z
Cancer Med; 2024 May; 13(9):e7232. PubMed ID: 38698679
[TBL] [Abstract][Full Text] [Related]
7. Daratumumab-lenalidomide and daratumumab-pomalidomide in relapsed lenalidomide-exposed or refractory multiple myeloma.
Alhaj Moustafa M; Parrondo R; Abdulazeez MF; Roy V; Sher T; Alegria VR; Warsame RM; Fonseca R; Rasheed A; Gonsalves WI; Kourelis T; Kapoor P; Buadi FK; Dingli D; Hayman SR; Reeder CB; Chanan-Khan AA; Ailawadhi S
Anticancer Drugs; 2024 Jan; 35(1):63-69. PubMed ID: 37067996
[TBL] [Abstract][Full Text] [Related]
8. Daratumumab for patients with myeloma with early or late relapse after initial therapy: subgroup analysis of CASTOR and POLLUX.
Spencer A; Moreau P; Mateos MV; Goldschmidt H; Suzuki K; Levin MD; Sonneveld P; Orlowski RZ; Yoon SS; Usmani SZ; Weisel K; Reece D; Ahmadi T; Pei H; Mayo WG; Gai X; Carey J; Bartlett JB; Carson R; Dimopoulos MA
Blood Adv; 2024 Jan; 8(2):388-398. PubMed ID: 38048391
[TBL] [Abstract][Full Text] [Related]
9. ANCHOR: melflufen plus dexamethasone and daratumumab or bortezomib in relapsed/refractory multiple myeloma: final results of a phase I/IIa study.
Ocio EM; Efebera YA; Hájek R; Straub J; Maisnar V; Eveillard JR; Karlin L; Mateos MV; Oriol A; Ribrag V; Richardson PG; Norin S; Obermüller J; Bakker NA; Pour L
Haematologica; 2024 Mar; 109(3):867-876. PubMed ID: 37646657
[TBL] [Abstract][Full Text] [Related]
10. [Efficacy of different regimens and prognostic factors in patients with first relapsed multiple myeloma treated after front-line bortezomib, cyclophosphamide, and dexamethasone].
Chen M; Fan Q; Li H; Ma YP; Qin XQ; Suo XH; Yang C; Zhu TN; Duan MH; Han B; Wang SJ; Zhou DB; Zhuang JL
Zhonghua Nei Ke Za Zhi; 2023 Dec; 62(12):1436-1443. PubMed ID: 38044070
[No Abstract] [Full Text] [Related]
11. Experience of Daratumumab in Relapsed/Refractory Multiple Myeloma: A Multicenter Study from Türkiye.
Tekinalp A; Gedük A; Akdeniz A; Terzi Demirsoy E; Gürsoy V; Aslaner Ak M; Bağcı M; Seçilmiş S; Keklik Karadağ F; Oruç Uysal A; Doğan A; Demircioğlu S; Erol HA; Aslan C; Özkalemkaş F; Ertop Ş; Dağlı M; Dal MS; Saydam G; Merter M; Ural C; Çeneli Ö
Turk J Haematol; 2023 Dec; 40(4):242-250. PubMed ID: 37961952
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of anti-CD38 monoclonal antibodies in patients with relapsed/refractory multiple myeloma: a systematic review and meta-analysis with trial sequential analysis of randomized controlled trials.
Ye L; Zhou F; Cheng D; Xie M; Yan X; Xue Y; Yang Q; Jia R; Zhong L; Yang L; Zou L; Huang N
Front Oncol; 2023; 13():1240318. PubMed ID: 38144527
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of Daratumumab, Pomalidomide, and Dexamethasone (DPd) Compared to Daratumumab, Bortezomib, and Dexamethasone (DVd) in Daratumumab-Naïve Relapsed Multiple Myeloma.
Afrough A; Atrash S; Paul B; Ouchveridze E; Ahmed N; Mahmoudjafari Z; Bashir A; Alkharabsheh O; Hashmi H; Abdallah AO
Cancers (Basel); 2023 Oct; 15(19):. PubMed ID: 37835587
[TBL] [Abstract][Full Text] [Related]
14. Daratumumab provides a survival benefit in relapsed and refractory Multiple Myeloma, independent of baseline clinical characteristics: A meta-analysis.
Cao C; Zhou X; Ma Q
Pharmacol Res Perspect; 2021 Aug; 9(4):e00797. PubMed ID: 34128350
[TBL] [Abstract][Full Text] [Related]
15. [Daratumumab maintenance after autologous hematopoietic stem cell transplantation for newly diagnosed multiple myeloma].
Ma Y; Xiao XB; Chen XL; Yuan SZ; Lu Y; Zhao SH; Chen JL; Shi GN; Wang YQ; Cheng NN; Feng P; Ding MS; Huang WR
Zhonghua Xue Ye Xue Za Zhi; 2023 Dec; 44(12):1016-1021. PubMed ID: 38503525
[No Abstract] [Full Text] [Related]
16. Role of daratumumab in the frontline management of multiple myeloma: a narrative review.
Yadav S; Gundeti S; Bhave A; Deb U; Dixit J; Mishra K
Expert Rev Hematol; 2023; 16(10):743-760. PubMed ID: 37585685
[TBL] [Abstract][Full Text] [Related]
17. The lymphocyte/monocyte ratio predicts the efficacy of isatuximab plus pomalidomide in multiple myeloma patients.
Shimazu Y; Kanda J; Onda Y; Fuchida SI; Ohta K; Shimura Y; Kosugi S; Yamamura R; Matsuda M; Hanamoto H; Adachi Y; Anzai N; Hotta M; Fukushima K; Yagi H; Yoshihara S; Tanaka Y; Takakuwa T; Tanaka H; Shibayama H; Uoshima N; Hosen N; Ito T; Shimazaki C; Matsumura I; Kuroda J; Takaori-Kondo A; Hino M
Cancer Immunol Immunother; 2024 May; 73(7):135. PubMed ID: 38758239
[TBL] [Abstract][Full Text] [Related]
18. Hyperfractionated Cyclophosphamide and Dexamethasone Alone or in Combination with Daratumumab and/or Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma: A Single-Center Retrospective Analysis.
Shank BR; Primeaux B; Yeung EK; Horowitz SB; Lee IY; Roccograndi L; Feng L; Kaufman GP; Lee HC; Manasanch EE; Patel KK; Orlowski RZ; Weber DM; Becnel MR; Thomas SK
Clin Lymphoma Myeloma Leuk; 2023 Apr; 23(4):279-290. PubMed ID: 36797154
[TBL] [Abstract][Full Text] [Related]
19. Final analysis of carfilzomib, dexamethasone, and daratumumab vs carfilzomib and dexamethasone in the CANDOR study.
Usmani SZ; Quach H; Mateos MV; Landgren O; Leleu X; Siegel D; Weisel K; Shu X; Li C; Dimopoulos M
Blood Adv; 2023 Jul; 7(14):3739-3748. PubMed ID: 37163358
[TBL] [Abstract][Full Text] [Related]
20. Comparative Efficacy of Teclistamab Versus Current Treatments in Real-World Clinical Practice in the Prospective LocoMMotion Study in Patients with Triple-Class-Exposed Relapsed and/or Refractory Multiple Myeloma.
Moreau P; van de Donk NWCJ; Delforge M; Einsele H; De Stefano V; Perrot A; Besemer B; Pawlyn C; Karlin L; Manier S; Leleu X; Weisel K; Ghilotti F; Diels J; Elsada A; Morano R; Strulev V; Pei L; Kobos R; Smit J; Slavcev M; Mateos MV
Adv Ther; 2023 May; 40(5):2412-2425. PubMed ID: 36961654
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]